RedHill Biopharma Ltd.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Dror Ben-Asher
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 21 Ha’arba’a Street Tel Aviv TA Israel 6473921
- IPO Date
- Jan 7, 2013
- CIK
- 0001553846
- Website
- redhillbio.com
- Similar Companies
- Business
- RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily engaged in the development, acquisition, and commercialization of proprietary drugs addressing significant unmet medical needs in gastrointestinal, infectious diseases, and oncology sectors. Founded in 2009 and headquartered in Tel Aviv, Israel, the company markets FDA-approved gastrointestinal products including Talicia (a fixed-dose combination of omeprazole, amoxicillin and rifabutin for Helicobacter pylori infection), Aemcolo (rifamycin for travelers’ diarrhea), and Movantik (used for opioid-induced constipation). Its late-stage clinical pipeline comprises therapeutic candidates such as opaganib, an oral sphingosine kinase-2 inhibitor targeting multiple indications including GI-Acute Radiation Syndrome, COVID-19, and prostate cancer; RHB-204 for Crohn’s disease and pulmonary nontuberculous mycobacteria infection; RHB-102 for acute gastroenteritis and gastritis; and RHB-107 (upamostat), an oral serine protease inhibitor for COVID-19 and inflammatory gastrointestinal diseases. In recent developments, RedHill formed a strategic partnership with Cumberland Pharmaceuticals, which secured a $4 million investment for a 30% stake in RedHill’s global Talicia business with co-commercialization efforts in the U.S. to expand market reach. Additionally, the company signed licensing agreements to commercialize Talicia in new Middle East markets, including upfront and milestone payments with tiered royalties based on sales. RedHill has also successfully regained compliance with Nasdaq stockholders’ equity requirements, reinforcing its financial position. The company continues to advance its pandemic preparedness and medical countermeasures programs focused on oral, broad-acting antiviral and anti-inflammatory therapies suitable for stockpiling and easy distribution in emergencies. RedHill operates mainly in the U.S. market while maintaining its headquarters in Israel, targeting healthcare providers and patients requiring gastrointestinal, infectious disease, and oncology treatments. It leverages in-house commercialization capabilities alongside strategic partnerships to expand its product reach. The company’s strategy includes continuing clinical development of its advanced pipeline candidates, commercializing its approved products, and exploring additional acquisition opportunities to enhance its portfolio and commercial footprint in specialty pharmaceutical markets.
Company News
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Redhill Biopharma (NASDAQ:RDHL)
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results
Critical Analysis: Redhill Biopharma (NASDAQ:RDHL) versus Novartis (NYSE:NVS)
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
RedHill Biopharma Announces Up To $19.4 Million Private Placement
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
Bessor Announces Entering Option for the Redhill Property
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
Analyzing Redhill Biopharma (NASDAQ:RDHL) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)
Redhill Biopharma (NASDAQ:RDHL) Share Price Crosses Below 200-Day Moving Average – What’s Next?
Joint U.S. Commercialization of RedHill's Talicia® Commences
Redhill Biopharma (NASDAQ:RDHL) Share Price Passes Below 200-Day Moving Average – What’s Next?